Rahul Kakkar describes how PGI is being leveraged for both gene and cell therapy applications.

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company's gene writing platform...

Ring CEO Tuyen Ong introduces us to anelloviruses and describes the qualities that could make them compelling delivery vehicles. Animal...

Daniel de Boer describes how Axiomer harnesses the body's natural ADAR editing process to turn an A into an I, he covers NHP data for...

Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this...

Founder & CEO Tao Fu walks us through the company's ATTOBODY platform and discusses programs targeting IL31 and IL31 x IL13.

Emily Walsh Martin covers regulatory comments from FDA's Peter Marks, scientific updates on prime and base editing, and more.

Jason Cole describes how Gene Coding can deliver large sequences to the genome without viral vectors or RNA guides, and describes how...

TJ Cradick gives us a preview of which abstracts and technologies to watch this year, including the latest in gene editing methods and...

An early adopter and researcher of AI, Noam Auslander shares her opinion of the benefits of AI but also guardrails that should be...

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell...

Jack O'Meara describes Ochre's unique preclinical testing strategy as it develops siRNA drugs for liver diseases, and he touches on a...

CIC Partner Michael Anstey describes the firm's history and investment approach, lists some current investments, and offers advice for...

Dr. Jhoti discusses the history of Astex, shows us a state-of-the-art cryo-EM microscope they have on site, and highlights the three...

Kathryn Chapman has held many roles in town and is an expert on everything Cambridge's life sciences ecosystem has to offer.

CEO Derek Jones describes how the campus is designed to augment the public research taking place at Babraham Institute with a community of s

Executive director Cathy Tralau-Stewart describes how Milner fosters partnerships.

Kevin Lee shows us what a bicycle looks like and compares and contrasts them to traditional antibodies.

Lindy Durrant describes Scancell's DNA and peptide based vaccine programs, as well as early stage antibody work.

Sofía Castelli describes what her path was to pursuing a PhD at UPenn, what it is like working in the lab of Dr. Carl June, and she...